Showing results (131-140 of 147) with videos related to
Sort By:
Pageof 15
Acta Psychiatrica Scandinavica|March 18, 2025
Confusional States During Electroconvulsive Therapy for Late-Life Depression: A Prospective Cohort StudyThomas C Feenstra, Nathalie Denayer, Kristof Vansteelandt, et al.Brain Stimulation|July 26, 2024
Characterization of gray matter volume changes from one week to 6 months after termination of electroconvulsive therapy in depressed patientsMaarten Laroy, Filip Bouckaert, Olga Therese Ousdal, et al.BMC Psychiatry|March 1, 2013
Methylphenidate in mania project (MEMAP): study protocol of an international randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidateMichael Kluge, Ulrich Hegerl, Christian Sander, et al.Journal of Geriatric Psychiatry and Neurology|February 11, 2020
Are Apathy and Depressive Symptoms Related to Vascular White Matter Hyperintensities in Severe Late Life Depression?Mardien Leoniek Oudega, Amna Siddiqui, Mike P Wattjes, et al.European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|November 28, 2017
A multi-centre, randomised, double-blind, placebo-controlled clinical trial of methylphenidate in the initial treatment of acute mania (MEMAP study)Ulrich Hegerl, Roland Mergl, Christian Sander, et al.European Journal of Medical Genetics|August 14, 2016
Copy number variation analysis in adults with catatonia confirms haploinsufficiency of SHANK3 as a predisposing factorJeroen Breckpot, Marieke Vercruyssen, Eddy Weyts, et al.The Journal of ECT|April 24, 2022
Preliminary Assessment of Pre-Electroconvulsive Therapy Evaluation Practices in European Countries: The Need for GuidelinesSara Medved, Nikola Žaja, Gabor Gazdag, et al.Brain Stimulation|July 30, 2023
Effective resting-state connectivity in severe unipolar depression before and after electroconvulsive therapyFreek Ten Doesschate, Willem Bruin, Peter Zeidman, et al.Frontiers in Psychiatry|August 1, 2022
Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methodsMarieke J Henstra, Thomas C Feenstra, Rob M Kok, et al.Schizophrenia Bulletin|October 8, 2021
Neural Substrates of Psychotic Depression: Findings From the Global ECT-MRI Research CollaborationAkihiro Takamiya, Annemiek Dols, Louise Emsell, et al.Pageof 15